A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC.
Phase of Trial: Phase II/III
Latest Information Update: 27 May 2016
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 10 May 2011 Results presented at Digestive Disease Week 2011.
- 02 Jun 2010 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
- 02 Jun 2010 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History